Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mechanisms of Pinometostat (EPZ-5676) Treatment–Emergent Resistance in MLL -Rearranged Leukemia

20 Apr 2017

Abstract excerpt

Abstract DOT1L is a protein methyltransferase involved in the development and maintenance of MLL-rearranged (MLL-r) leukemia through its ectopic methylation of histones associated with well-characterized leukemic genes. Pinometostat (EPZ-5676), a selective inhibitor of DOT1L, is in clinical development in relapsed/refractory acute leukemia patients harboring rearrangements of the MLL gene. The observation of...

Topics

Join the communities discussing this publication.

Acute Myeloid Leukemia Research
Cancer-related gene regulation
Epigenetics and DNA Methylation

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 28428443
DOI: 10.1158/1535-7163.mct-16-0693

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mechanisms of Pinometostat (EPZ-5676) Treatment–Emergent Resistance in MLL -Rearranged LeukemiaPMID 28428443Read ↗

Final Report of Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676), in Children with Relapsed or Refractory MLL-r Acute LeukemiaSemantic proximity Read ↗

Inhibition of Methyltransferase DOT1L Sensitizes to Sorafenib Treatment AML Cells Irrespective of MLL-Rearrangements: A Novel Therapeutic Strategy for Pediatric AMLSemantic proximity Read ↗

Distinct Responses to Menin Inhibition and Synergy with DOT1L Inhibition in KMT2A-Rearranged Acute Lymphoblastic and Myeloid Leukemia.Semantic proximity Read ↗

Potent inhibition of DOT1L as treatment of MLL-fusion leukemiaSemantic proximity Read ↗

Epigenetic enzyme mutations as mediators of anti-cancer drug resistance.Semantic proximity Read ↗

MLL partial tandem duplication leukemia cells are sensitive to small molecule DOT1L inhibitionSemantic proximity Read ↗

DOT1L Inhibition Sensitizes MLL-Rearranged AML to ChemotherapySemantic proximity Read ↗

Novel inhibitors of the histone methyltransferase DOT1L show potent antileukemic activity in patient-derived xenograftsSemantic proximity Read ↗

Acquired resistance to PRMT5 inhibition induces concomitant collateral sensitivity to paclitaxel.Semantic proximity Read ↗

Upfront Menin-inhibitor resistance in multiply pretreated leukemiasSemantic proximity Read ↗

The Menin Inhibitor SNDX-5613 (revumenib) Leads to Durable Responses in Patients (Pts) with KMT2A-Rearranged or NPM1 Mutant AML: Updated Results of a Phase (Ph) 1 StudySemantic proximity Read ↗

S125: NON-GENETIC RESISTANCE TO MENIN INHIBITION IN AML IS REVERSIBLE BY PERTURBATION OF KAT6ASemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.